Testagen

What it is

Testagen belongs to the cytogens, the synthetic short peptides of the Khavinson school. The sequence is clearly documented: lysine, glutamic acid, aspartic acid, glycine. It differs from Epitalon, the best-known peptide in the series with the sequence Ala-Glu-Asp-Gly, only in the first amino acid.

The name suggests a testis peptide, and that is how it is marketed. In the research literature, however, KEDG appears in a different context. A group led by Boris Kuznik describes it as a peptide synthesized according to the amino acid composition of peptide complexes from the anterior pituitary. The pituitary controls, among other things, the thyroid, the adrenal glands and the gonads. A link to testicular function is therefore not ruled out, but it has never been studied.

A 2020 review by the Khavinson group also lists KEDG among the peptides that stimulate the differentiation of immune cells, and a Romanian paper from 2025 describes it as a bioregulator that is said to stimulate the functions of the endocrine system.

How it is supposed to work

Like the other short peptides of the school, KEDG is said to enter the cell and the cell nucleus and influence the reading of genes there. For Testagen, the first step has been shown: labeled with a fluorescent dye, it was found in HeLa cells in the cytoplasm, in the nucleus and in the nucleolus. In the test tube, it bound preferentially to DNA segments with the sequence CAG, similar to Epitalon and Pinealon.

What is then supposed to happen in testicular tissue remains a claim. The idea that Testagen activates testis- and prostate-specific genes appears in many product descriptions. A study that measured this in testicular or prostate cells, in animals or in humans, could not be found.

What the bird studies show

The most solid data on KEDG come from a series of experiments on chickens whose pituitary gland had been removed. Without a pituitary, the thyroid atrophies, the immune system weakens and blood clotting becomes unbalanced. When the animals were given KEDG for 40 days, thyrotropin and the thyroid hormones T3 and T4 rose again, and the structure of the thyroid recovered. Immune and clotting values also normalized.

In older animals the effect was weaker than in young ones: one-year-old birds responded better than five-year-old ones, and in old hens the effect on thyroid hormones was smaller than in chicks. In another paper, KEDG promoted the recovery of the thymus more strongly than its counterpart from the posterior pituitary.

From these findings, the group derived a Russian patent: KEDG as an agent intended to stimulate the formation of thyrotropin in the pituitary and of thyroid hormones in secondary hypothyroidism. According to the data, the obvious application of the molecule therefore lies with the pituitary and thyroid, not with the testes.

Three mix-ups

Around Testagen, information circulates that belongs to other products. First, Prostamax: this peptide has the sequence Lys-Glu-Asp-Pro and is a different molecule. Papers by the Tbilisi group on lymphocytes of elderly people concern Prostamax, not Testagen, but are occasionally attributed to Testagen.

Second, the Russian studies on benign prostatic enlargement. They examine Prostatilen, an extract of prostate tissue, for example in 96 patients aged 51 to 89, or Chitomur, a bladder peptide, in a placebo-controlled study in men aged 62 to 83. They have nothing to do with Testagen.

Third, a testosterone product for application to the skin, listed in a trial registry under the name Testagen TDS-Testosterone. Anyone searching for Testagen studies easily ends up there. It has nothing in common with the peptide except the name.

What the studies show

Thyroid of hypophysectomized chicks (2008)

Kuznik and colleagues gave KEDG and the related AEDG for 40 days to chicks whose pituitary had been removed shortly after hatching. Thyrotropin and thyroid hormones rose, and the thyroid structure recovered. Both peptides were synthesized according to the composition of pituitary extracts.

Young and old birds compared (2011)

In two follow-up papers, chicks and old hens as well as one- and five-year-old birds were compared. The peptides reduced the hormonal disturbances and structural damage after removal of the pituitary, less markedly in older animals. T3 and T4 rose again.

Thymus after pituitary removal (2013)

Pateyk and colleagues examined the thymus of hypophysectomized young and old birds. Both peptides promoted the restoration of thymus structure, the anterior lobe peptide KEDG more strongly than AEDG.

Copper instead of the body (2025)

A Romanian materials research group bought the peptide as Testagen and tested it as a corrosion inhibitor for copper in salt solution, with an inhibition efficiency of around 86 percent. This says nothing about its effect in the body, but it shows how freely KEDG is traded under this name.

Where the data stop

For the applications with which Testagen is sold, there are no data. No study examines KEDG on the testes, prostate, sperm, libido or testosterone, whether in cells, in animals or in humans. There is no human study, not even laboratory work on human cells with Testagen, and on ClinicalTrials.gov only the testosterone product is found under that name.

The existing animal data also have limits. They come from birds whose pituitary had been removed, that is, from a model in which an entire hormonal system is missing. Whether KEDG has any effect in mammals with an intact pituitary has not been studied. And the papers come from a single Russian group without independent replication.

Status, approval and legal

Testagen is not an approved medicine in Germany or the EU. As a dietary supplement it would require authorization under the Novel Food Regulation (EU) 2015/2283, which does not exist. It is traded as a capsule product or research peptide via online retailers. It is not named on the World Anti-Doping Agency’s Prohibited List, but as a non-approved substance it falls under group S0 and is prohibited in sport at all times. The testosterone product of the same name would in any case be prohibited as testosterone under group S1.

Safety

There are no safety data in humans, and no published toxicology could be found. Because KEDG altered thyroid hormones in bird studies, caution is advisable in thyroid disease and with thyroid medication, even though this has never been tested in humans. Anyone with urinary complaints, testosterone deficiency, fertility problems or prostate disease needs a urological or endocrinological assessment; Testagen does not replace diagnosis or treatment. With research-grade products, content and purity are unverified.

Sources

• Fedoreyeva et al., Biochemistry (Mosc) 2011 – Epitalon, Pinealon and Testagen enter the cell nucleus
• Kuznik et al., Bull Exp Biol Med 2008 – KEDG and AEDG in hypophysectomized chicks
• Kuznik et al., Bull Exp Biol Med 2011 – KEDG and AEDG in young chicks and old hens
• Pateyk et al., Bull Exp Biol Med 2013 – KEDG and the thymus of hypophysectomized birds
• Khavinson et al., Stem Cell Rev Rep 2020 – peptide regulation of cell differentiation (review)
• Dobriţescu et al., Molecules 2025 – Testagen (KEDG) as a corrosion inhibitor for copper
• Dzhokhadze et al., Georgian Med News 2012 – Prostamax is Lys-Glu-Asp-Pro
• Al-Shukri et al., Urologiia 2005 – Prostatilen in benign prostatic enlargement
• ClinicalTrials.gov – NCT02733133, testosterone product of the same name
• NADA – Prohibited List 2026, informational German translation (groups S0 and S1)